Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology ...

And then there were two. Senti Bio, seeing the end of its cash runway hove into view, has pulled the plug on its liver cancer candidate and narrowed its focus onto two CAR-NK programs to preserve its ...

Senti Biosciences, Inc. (NASDAQ:SNTI) has rebounded strongly over the last week, with the share price soaring 68%. But that's not enough to compensate for the decline over the last twelve months.

Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology ...

Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro. The ...

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today ...

Senti Biosciences’ solid tumor drug will be tested in an early-stage trial in China next year through a $156 million biobucks deal with Shanghai-based Celest Therapeutics. SENTI-301A is an ...

Senti Bio released a KOL segment discussing leukemia research and its lead program, SENTI-202, featuring Drs. Strickland and Rajangam. Senti Biosciences, Inc. has released a Virtual Investor KOL ...

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and ...

Senti Biosciences Inc (NASDAQ:SNTI) shares are trading higher by 102.6% to $0.56 during Monday’s session after the company was awarded $8 million from the California Institute for Regenerative ...

In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference, and ...

Senti Biosciences, Inc. has announced that its CEO, Timothy Lu, participated in Nasdaq's Amplify Spotlight Series, where he discussed the company's proprietary Gene Circuit platform aimed at ...